Frontier Medicines is a clinical-stage precision medicine company that leverages its proprietary Frontier Platform, a chemoproteomics-powered drug discovery engine using covalent chemistry and machine learning, to unlock hard-to-treat disease-causing proteins. The company is advancing a diversified pipeline of wholly-owned precision medicines focused on oncology and high-value immunology targets. Its lead candidate, FMC-376, is a dual ON+OFF KRASG12C inhibitor currently in the Phase 1/2 PROSPER trial (NCT06244771) and is designed to overcome resistance seen with single-acting KRASG12C inhibitors. Frontier has stated a goal of filing one IND per year as it progresses its programs. The company recently raised additional capital to support development of FMC-376 and to accelerate other preclinical and pipeline programs. Headquarters are listed as Boston and South San Francisco, California. Frontier Medicines is a clinical-stage precision medicine company based in Boston and San Francisco focused on therapies for genetically-defined patient populations in oncology and immunology. Its core product is the Frontier™ Platform, a chemoproteomics-empowered drug discovery engine that leverages covalent chemistry and machine learning to target hard-to-treat disease-causing proteins. The company is advancing a diversified pipeline of wholly-owned precision medicines, with lead candidate FMC-376, a dual inhibitor of on- and off-state KRASG12C. Frontier intends to use the new capital to advance multiple programs, including FMC-376, into clinical studies. The firm is led by CEO Chris Varma and emphasizes transforming treatment for genetically-defined patients. No revenue or user metrics were disclosed in the article. Frontier Medicines deploys integrated technologies in chemoproteomics, covalent drug discovery, and machine learning to generate medicines against proteins previously considered undruggable. The company is advancing a wholly-owned precision oncology pipeline, with a lead program that uniquely targets both the activated and inactive forms of KRASG12C. Frontier intends to use its platform to expand pipeline opportunities across therapeutic areas by leveraging identified protein hotspots. Proceeds from the recent financing are designated to advance research and development of its pipeline and to accelerate foundational technologies across chemoproteomics, covalent discovery, and machine learning. The company also announced a distinguished Scientific Advisory Board to support its programs and highlighted a substantial protein degradation partnership with AbbVie announced late last year. Frontier is expanding operations with a new Boston facility integrated with its South San Francisco headquarters to support bi-coastal growth and R&D capabilities. Frontier Medicines is a pre-clinical stage biopharmaceutical company developing medicines to redefine the course of debilitating diseases, starting with cancer. The company uses a proprietary chemoproteomics platform to chemically interrogate proteins in living systems and identify new binding pockets accessible to small-molecule drug discovery. Its platform also integrates advanced computational approaches and machine learning to accelerate drug discovery. Frontier intends to advance multiple therapeutic programs leveraging this platform. The company closed a $67M Series A to fund research and development, talent acquisition, and advancement of its platform and programs. Co-founders include Chris Varma (CEO), Roberto Zoncu, Ph.D., and Daniel K. Nomura, Ph.D.

Total raised

$256M

Funding rounds

4

Latest round

Series C

Latest activity

Jun 2024